This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by De Leeuw, K Articles by Bijl, M Search for Related Content PubMed PubMed Citation Articles by De Leeuw, K Articles by Bijl, M Social Bookmarking                   What's this?

Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus

Division of Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ or PO Box 30.001, 9700 RB, Groningen, The Netherlands.k.de.leeuw{at}int.umcg.nl

B Freire

Division of Rheumatology and Clinical Immunology;

A J Smit

Division of Vascular Diseases, Department of Internal Medicine, University Medical Center, Groningen, The Netherlands

H Bootsma

C G Kallenberg

M Bijl

Division of Rheumatology and Clinical Immunology;

To determine risk factors of accelerated atherosclerosis in patients with systemic lupus erythematosus (SLE), 72 patients with inactive disease and 36 ageand sex-matched controls were included. The intima-media thickness (IMT) of the common carotid artery was determined by ultrasound. Traditional risk factors and disease-related factors were recorded. Cardiovascular risk was estimated using SCORE (systematic coronary risk evaluation). Markers of inflammation, endothelial activation and vascular remodelling (matrix metalloproteinases (MMP-3, MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1)) were determined.

IMT was increased in patients (0.67 mm 0.13 versus 0.61 mm 0.11,P 0.05). Prevalence of hypertension (33% versus 6%,P 0.001), SCORE (2.2 (1.7–4.2) versus 1.7 (1.3–2.1),P 0.001), as well as parameters of inflammation (CRP 1.8 (0.6–5.8) mg/L versus 0.6 (0.2–1.0) mg/L,P 0.001) and endothelial activation (VCAM-1 505 (389–683) ng/mL versus 374 (322–427) ng/mL,P 0.001) and von Willebrand factor (138 (59–208)% versus 48 (24–92)%,P 0.001), were increased in patients. Vascular remodelling was altered: MMP-3 and TIMP-1 were increased (18 (10–29) ng/mL versus 8 (5–11) ng/mL,P 0.001, and 275 (216–352) ng/mL versus 230 (197–268) ng/mL,P 0.001, respectively), and MMP-9 was decreased in SLE (266 (147–412) ng/mL versus 348 (226–530) ng/mL, P 0.05).

Univariate analyses revealed that in patients IMT was associated with age, systolic blood pressure, SCORE and disease duration. In multivariate analysis, age and SCORE were independent predictors of IMT.

In conclusion, SLE patients have an increased IMT, which is associated with traditional risk factors. Non-traditional risk factors, such as endothelial activation, altered vascular remodelling and disease duration, might play an additional role.

Key Words: atherosclerosis • risk factors • systemic lupus erythematosus

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. L. Nienhuis, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts Rheumatology, August 13, 2008; (2008) ken302v1. [Abstract] [Full Text] [PDF]

				M. E. Hettema, H. Bootsma, and C. G. M. Kallenberg Macrovascular disease and atherosclerosis in SSc Rheumatology, May 1, 2008; 47(5): 578 - 583. [Abstract] [Full Text] [PDF]

				M. J. Roman and J. E. Salmon Cardiovascular Manifestations of Rheumatologic Diseases Circulation, November 13, 2007; 116(20): 2346 - 2355. [Full Text] [PDF]

				G. D Azevedo, R. G N Gadelha, and M. J. Vilar Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA Ann Rheum Dis, November 1, 2007; 66(11): 1542 - 1542. [Full Text] [PDF]

				K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF]